SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-023329
Filing Date
2021-05-04
Accepted
2021-05-04 16:07:32
Documents
13
Period of Report
2021-05-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K atra-8k_20210504.htm   iXBRL 8-K 38845
2 EX-99.1 atra-ex991_69.htm EX-99.1 258940
  Complete submission text file 0001564590-21-023329.txt   442590

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA atra-20210504.xsd EX-101.SCH 5776
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE atra-20210504_lab.xml EX-101.LAB 19469
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atra-20210504_pre.xml EX-101.PRE 11630
6 EXTRACTED XBRL INSTANCE DOCUMENT atra-8k_20210504_htm.xml XML 3576
Mailing Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080 650-278-8930
Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)

IRS No.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36548 | Film No.: 21888456
SIC: 2836 Biological Products, (No Diagnostic Substances)